Hypolipidemic and cardioprotective effects of statins can be associated with the development of myopathies and new-onset type 2 diabetes. These adverse effects may be related to increased oxidative stress. The plant extract silymarin (SM) is known for its antioxidant and anti-inflammatory actions. We tested the hypothesis that the combination of atorvastatin (ATV) with SM could improve therapy efficacy and eliminate some negative effects of statin on hypertriglyceridemia-induced metabolic disorders. Hereditary hypertriglyceridemic rats were fed a standard diet for four weeks without supplementation; supplemented with ATV (5 mg/kg b. wt./day) or a combination of ATV with 1 % micronized SM (ATV+SM). ATV treatment elevated plasma levels of HDL-cholesterol (p<0.01), glucose and insulin and decreased triglycerides (p<0.001). The combination of ATV+SM led to a significant reduction in insulin, an improvement of glucose tolerance, and the hypolipidemic effect was enhanced compared to ATV alone. Furthermore, ATV supplementation increased skeletal muscle triglycerides but its combination with SM decreased triglycerides accumulation in the muscle (p<0.05) and the liver (p<0.01). In the liver, ATV+SM treatment increased the activities of antioxidant enzymes, glutathione and reduced lipid peroxidation (p<0.001). The combined administration of ATV with SM potentiated the hypolipidemic effect, reduced ectopic lipid accumulation, improved glucose metabolism, and increased antioxidant and anti-inflammatory actions. Our results show that SM increased the effectiveness of statin therapy in a hypertriglyceridemic rat model of metabolic syndrome.

Centre for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

AIMAN U, NAJMI A, KHAN RA. Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother. 2014;5:181–185. doi: 10.4103/0976-500X.136097. PubMed DOI PMC

BANACH M, PATTI AM, GIGLIO RV, CICERO AFG, ATANASOV AG, BAJRAKTARI G, BRUCKERT E, DESCAMPS O, DJURIC DM, EZHOV M, FRAS Z, Von HAEHLING S, KATSIKI N, LANGLOIS M, LATKOVSKIS G, MANCINI GBJ, MIKHAILIDIS DP, MITCHENKO O, MORIARTY PM, MUNTNER P, ET AL. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72:96–118. doi: 10.1016/j.jacc.2018.04.040. PubMed DOI

BOREN J, TASKINEN MR, OLOFSSON SO, LEVIN M. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med. 2013;274:25–40. doi: 10.1111/joim.12071. PubMed DOI

BOUITBIR J, SANVEE GM, PANAJATOVIC MV, SINGH F, KRAHENBUHL S. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol Res. 2020;154:104201. doi: 10.1016/j.phrs.2019.03.010. PubMed DOI

CASULA M, MOZZANICA F, SCOTTI L, TRAGNI E, PIRILLO A, CORRAO G, CATAPANO AL. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017;27:396–406. doi: 10.1016/j.numecd.2017.03.001. PubMed DOI

DEVARAJ S, SINGH U, JIALAL I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20:182–189. doi: 10.1097/MOL.0b013e32832ac03e. PubMed DOI PMC

Di COSTANZO A, ANGELICO R. Formulation strategies for enhancing the bioavailability of silymarin: The state of the art. Molecules. 2019;24:2155. doi: 10.3390/molecules24112155. PubMed DOI PMC

EBERLE D, HEGARTY B, BOSSARD P, FERRE P, FOUFELLE F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86:839–848. doi: 10.1016/j.biochi.2004.09.018. PubMed DOI

EBRAHIMPOUR-KOUJAN S, GARGARI BP, MOBASSERI M, VALIZADEH H, ASGHARI-JAFARABADI M. Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L. Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial. Phytomedicine. 2018;44:39–44. doi: 10.1016/j.phymed.2018.03.050. PubMed DOI

GILLESSEN A, SCHMIDT HH. Silymarin as supportive treatment in liver diseases: A narrative review. Adv Ther. 2020;37:1279–1301. doi: 10.1007/s12325-020-01251-y. PubMed DOI PMC

GU M, ZHAO P, HUANG J, ZHAO Y, WANG Y, LI Y, LI Y, FAN S, MA YM, TONG Q, YANG L, JI G, HUANG C. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor. Front Pharmacol. 2016;7:345. doi: 10.3389/fphar.2016.00345. PubMed DOI PMC

GUO Y, WANG S, WANG Y, ZHU T. Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice. Pharm Biol. 2016;54:2995–3000. doi: 10.1080/13880209.2016.1199042. PubMed DOI

JAVED S, KOHLI K, ALI M. Reassessing bioavailability of silymarin. Altern Med Rev. 2011;16:239–249. PubMed

KAMISAKO T, OGAWA H. Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat. J Gastroenterol Hepatol. 2004;19:879–883. doi: 10.1111/j.1440-1746.2004.03377.x. PubMed DOI

MACH F, RAY KK, WIKLUND O, CORSINI A, CATAPANO AL, BRUCKERT E, De BACKER G, HEGELE RA, HOVINGH GK, JACOBSON TA, KRAUSS RM, LAUFS U, LEITER LA, MARZ W, NORDESTGAARD BG, RAAL FJ, RODEN M, SANTOS RD, STEIN EA, STROES ES, ET AL. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39:2526–2539. doi: 10.1093/eurheartj/ehy182. PubMed DOI PMC

MALINSKA H, ŠKOP V, TRNOVSKA J, MARKOVA I, SVOBODA P, KAZDOVA L, HALUZIK M. Metformin attenuates myocardium dicarbonyl stress induced by chronic hypertriglyceridemia. Physiol Res. 2018;67:181–189. doi: 10.33549/physiolres.933606. PubMed DOI

MALINSKA H, OLIYARNYK O, HUBOVA M, ZIDEK V, LANDA V, SIMAKOVA M, MLEJNEK P, KAZDOVA L, KURTZ TW, PRAVENEC M. Increased liver oxidative stress and altered PUFA metabolism precede development of non-alcoholic steatohepatitis in SREBP-1a transgenic spontaneously hypertensive rats with genetic predisposition to hepatic steatosis. Mol Cell Biochem. 2010;335:119–125. doi: 10.1007/s11010-009-0248-5. PubMed DOI

MIHOS CG, PINEDA AM, SANTANA O. Cardiovascular effects of statins, beyond lipid-lowering properties. Pharmacol Res. 2014;88:12–19. doi: 10.1016/j.phrs.2014.02.009. PubMed DOI

NEHA, JAGGI AS, SINGH N. Silymarin and its role in chronic diseases. Adv Exp Med Biol. 2016;929:25–44. doi: 10.1007/978-3-319-41342-6_2. PubMed DOI

PORUBA M, KAZDOVA L, OLIYARNYK O, MALINSKA H, MATUSKOVA Z, TOZZI DI ANGELO I, SKOP V, VECERA R. Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome. Xenobiotica. 2015a;45:751–756. doi: 10.3109/00498254.2015.1010633. PubMed DOI

PORUBA M, MATUSKOVA Z, KAZDOVA L, OLIYARNYK O, MALINSKA H, TOZZI Di ANGELO I, VECERA R. Positive effects of different drug forms of silybin in the treatment of metabolic syndrome. Physiol Res. 2015b;64(Suppl 4):S507–S512. doi: 10.33549/physiolres.933235. PubMed DOI

PORUBA M, ANZENBACHER P, RACOVA Z, OLIYARNYK O, HUTTL M, MALINSKA H, MARKOVA I, GURSKA S, KAZDOVA L, VECERA R. The effect of combined diet containing n-3 polyunsaturated fatty acids and silymarin on metabolic syndrome in rats. Physiol Res. 2019;68(Suppl 1):S39–S50. doi: 10.33549/physiolres.934322. PubMed DOI

QI N, KAZDOVA L, ZIDEK V, LANDA V, KREN V, PERSHADSINGH HA, LEZIN ES, ABUMRAD NA, PRAVENEC M, KURTZ TW. Pharmacogenetic evidence that CD36 is a key determinant of the metabolic effects of pioglitazone. J Biol Chem. 2002;277:48501–48507. doi: 10.1074/jbc.M206655200. PubMed DOI

REHMAN K, AKASH MSH, LIAQAT A, KAMAL S, QADIR MI, RASUL A. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr. 2017;27:229–236. doi: 10.1615/CritRevEukaryotGeneExpr.2017019712. PubMed DOI

SALAMI JA, WARRAICH H, VALERO-ELIZONDO J, SPATZ ES, DESAI NR, RANA JS, VIRANI SS, BLANKSTEIN R, KHERA A, BLAHA MJ, BLUMENTHAL RS, LLOYD-JONES D, NASIR K. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2:56–65. doi: 10.1001/jamacardio.2016.4700. PubMed DOI

SATTAR N, PREISS D, MURRAY HM, WELSH P, BUCKLEY BM, De CRAEN AJ, SESHASAI SR, McMURRAY JJ, FREEMAN DJ, JUKEMA JW, MacFARLANE PW, PACKARD CJ, STOTT DJ, WESTENDORP RG, SHEPHERD J, DAVIS BR, PRESSEL SL, MARCHIOLI R, MARFISI RM, MAGGIONI AP, ET AL. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–742. doi: 10.1016/S0140-6736(09)61965-6. PubMed DOI

SILVERMAN MG, FERENCE BA, IM K, WIVIOTT SD, GIUGLIANO RP, GRUNDY SM, BRAUNWALD E, SABATINE MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA. 2016;316:1289–1297. doi: 10.1001/jama.2016.13985. PubMed DOI

SKOTTOVA N, KAZDOVA L, OLIYARNYK O, VECERA R, SOBOLOVA L, ULRICHOVA J. Phenolics-rich extracts from Silybum marianum and Prunella vulgaris reduce a high-sucrose diet induced oxidative stress in hereditary hypertriglyceridemic rats. Pharmacol Res. 2004;50:123–130. doi: 10.1016/j.phrs.2003.12.013. PubMed DOI

SOBOLOVA L, SKOTTOVA N, VECERA R, URBANEK K. Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats. Pharmacol Res. 2006;53:104–112. doi: 10.1016/j.phrs.2005.09.004. PubMed DOI

STEFAN N, MACHANN J, SCHICK F, CLAUSSEN CD, THAMER C, FRITSCHE A, HARING HU. New imaging techniques of fat, muscle and liver within the context of determining insulin sensitivity. Horm Res. 2005;64(Suppl 3):38–44. doi: 10.1159/000089316. PubMed DOI

SURAI PF. Silymarin as a natural antioxidant: An overview of the current evidence and perspectives. Antioxidants (Basel) 2015;4:204–247. doi: 10.3390/antiox4010204. PubMed DOI PMC

TANGVARASITTICHAI S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6:456–480. doi: 10.4239/wjd.v6.i3.456. PubMed DOI PMC

Van ROOYEN DM, FARRELL GC. SREBP-2: a link between insulin resistance, hepatic cholesterol, and inflammation in NASH. J Gastroenterol Hepatol. 2011;26:789–792. doi: 10.1111/j.1440-1746.2011.06704.x. PubMed DOI

VELUSSI M, CERNIGOI AM, De MONTE A, DAPAS F, CAFFAU C, ZILLI M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26:871–879. doi: 10.1016/S0168-8278(97)80255-3. PubMed DOI

VRANA A, KAZDOVA L. The hereditary hypertriglyceridemic nonobese rat: an experimental model of human hypertriglyceridemia. Transplant Proc. 1990;22:2579. PubMed

WARD NC, WATTS GF, ECKEL RH. Statin toxicity. Circ Res. 2019;124:328–350. doi: 10.1161/CIRCRESAHA.118.312782. PubMed DOI

YU ZW, LI D, LING WH, JIN TR. Role of nuclear factor (erythroid-derived 2)-like 2 in metabolic homeostasis and insulin action: A novel opportunity for diabetes treatment? World J Diabetes. 2012;3:19–28. doi: 10.4239/wjd.v3.i1.19. PubMed DOI PMC

ZICHA J, PECHANOVA O, CACANYIOVA S, CEBOVA M, KRISTEK F, TOROK J, SIMKO F, DOBESOVA Z, KUNES J. Hereditary hypertriglyceridemic rat: a suitable model of cardiovascular disease and metabolic syndrome? Physiol Res. 2006;55(Suppl 1):S49–S63. PubMed

Metabolic Syndrome in Hypertriglyceridemic Rats: Effects of Antioxidants

The Beneficial Additive Effect of Silymarin in Metformin Therapy of Liver Steatosis in a Pre-Diabetic Model